Faslodex® (fulvestrant) – Expanded indication
November 15, 2017 – AstraZeneca announced the FDA approval of Faslodex (fulvestrant) for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with Ibrance® (palbociclib) or Verzenio® (abemaciclib) in women with disease progression after endocrine therapy.
Top